• Explore /
  • Poster
  • / Association of gene signature to identify molecular subtypes with clinical outcomes of 1st-line cetuximab (cet) treatment for metastatic colorectal cancer (mCRC).

Association of gene signature to identify molecular subtypes with clinical outcomes of 1st-line cetuximab (cet) treatment for metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

Yu Sunakawa

Yu Sunakawa

Division of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan

Yu Sunakawa , Eva Wang , Chris Roberts , Dongyun Yang , Qian Liu , Debrah Thompson , Ihab Botros , Miriana Moran , Stephanie H. Astrow , Jack Hsiang , Wu Zhang , Sebastian Stintzing , Akihito Tsuji , Takehiro Takahashi , Tadamichi Denda , Masahiro Takeuchi , Masashi Fujii , Toshifusa Nakajima , Wataru Ichikawa , Heinz-Josef Lenz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Epidemiology/Outcomes

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3592)

DOI

10.1200/JCO.2016.34.15_suppl.3592

Abstract #

3592

Poster Bd #

289

Abstract Disclosures

Similar Posters

First Author: Yu Sunakawa

First Author: Yu Sunakawa

First Author: Jan Franko

First Author: Kaori Hayashi